Physician profile
Omar Obaid
NPI 1902292915
$4,805.09
in general payments reported to CMS, 2019-2025
25 companies · $394 in 2025
The $394 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $518 · 2022: $1,667 · 2023: $1,306 · 2024: $920 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,619.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $997.51 | 2021-2022 | |
| Medtronic, INC. | $546.57 | 2021-2025 | Abre, In.Pact Admiral |
| Boston Scientific Corporation | $511.41 | 2021-2025 | General - Atherectomy |
| Shockwave Medical, INC | $401.02 | 2022 | |
| Novartis Pharmaceuticals Corporation | $369.20 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $353.82 | 2022-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.93 | 2022-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $245.58 | 2023-2024 | Verquvo, Belsomra |
| Edwards Lifesciences Corporation | $210.36 | 2023-2025 | Pascal, Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $163.13 | 2021-2023 | Brilinta |
| Chiesi USA, INC. | $105.97 | 2022-2023 | Cleviprex, Kengreal |
| E.R. Squibb & Sons, L.L.C. | $91.63 | 2023-2024 | Eliquis |
| Abiomed | $80.77 | 2023 | Impella |
| W. L. Gore & Associates, INC. | $67.27 | 2023 | Gore Viabahn Endoprosthesis With Heparin, Gore Viabahn Vbx Balloon Expandable Endo |
| Janssen Pharmaceuticals, INC | $59.79 | 2022-2024 | Xarelto |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $55.77 | 2022-2024 | Nexletol |
| Scpharmaceuticals INC. | $53.99 | 2024 | |
| Abbott Laboratories | $45.76 | 2022-2023 | Cardiomems |
| Amgen INC. | $42.62 | 2023 | Repatha |
| Pfizer INC. | $39.11 | 2023-2024 | |
| Atricure, INC. | $21.58 | 2023 | |
| Inari Medical, INC. | $18.17 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $17.58 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $14.12 | 2023 | Cardiva Vascade 6/7f Vcs |
| Lexicon Pharmaceuticals, INC. | $13.43 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Obaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.